RTS,S malaria vaccine candidate
Final results from Phase III clinical trial including the impact of a booster dose announced
The latest results demonstrated that vaccination with RTS,S, followed by a booster dose of RTS,S administered 18 months after the primary schedule, reduced the number of cases of clinical malaria in children (aged 5-17 months at first vaccination) by 36% to the end of the study (over an average follow-up of 48 months across trial sites) and in infants (aged 6-12 weeks at first vaccination) by 26% to the end of the study (over an average follow-up of 38 months across trial sites). Efficacy decreased over time in both age groups. Without the booster dose, the 3-dose primary schedule reduced clinical malaria cases by 28% in children and 18% in infants to the study end. The efficacy of RTS,S was evaluated in the context of existing malaria control measures, such as insecticide treated bed nets, which were used by approximately 80% of the children and infants in the trial.
- Read the press release.
- Read The Lancet article.
- View related resources.
- Read about the Phase III results after 18 months of follow-up in 2013.
- Read about the Phase III results in 6 to 12-week-olds, released in 2012.
- Read about the Phase III results in 5 to 17-month-olds, released in 2011.